日本新薬の業績推移
(単位:百万円)
|
売上高 |
営業利益 |
経常利益 |
純利益 |
売上原価 |
売上総利益 |
株主資本 |
総負債 |
総資産 |
現金及び現金同等物 |
流動市場性有価証券 |
流動資産 |
流動負債 |
利益剰余金 |
営業利益率 |
経常利益率 |
当期利益率 |
自己資本比率 |
営業キャッシュフロー |
投資キャッシュフロー |
財務キャッシュフロー |
営業キャッシュフローマージン |
フリーキャッシュフロー |
ROE |
ROA |
一株あたり利益 |
希薄化後一株あたり利益 |
従業員数 |
2024年3月
|
148,255
|
33,295
|
33,616
|
25,851
|
50,234
|
98,021
|
220,534
|
42,870
|
263,404
|
58,094
|
|
164,285
|
37,336
|
198,260
|
22.46%
|
22.67%
|
17.44%
|
83.72%
|
16,289
|
-9,921
|
-9,719
|
10.99%
|
6,368
|
12.41%
|
10.32%
|
0.00038382
|
0.00033264
|
2213人
|
2023年3月
|
144,175
|
30,049
|
30,489
|
22,812
|
55,980
|
88,195
|
195,933
|
41,518
|
237,451
|
60,047
|
|
157,873
|
35,183
|
180,433
|
20.84%
|
21.15%
|
15.82%
|
82.52%
|
26,170
|
-17,631
|
-9,605
|
18.15%
|
8,539
|
12.11%
|
9.97%
|
0.0003387
|
0.0002965
|
2186人
|
2022年3月
|
137,547
|
32,948
|
33,301
|
24,986
|
50,191
|
87,356
|
180,886
|
39,057
|
219,943
|
60,566
|
|
149,724
|
32,029
|
165,303
|
23.95%
|
24.21%
|
18.17%
|
82.24%
|
21,316
|
-10,037
|
-8,407
|
15.5%
|
11,279
|
14.51%
|
11.75%
|
0.00037097
|
0.00034214
|
2125人
|
2021年3月
|
121,885
|
27,202
|
27,608
|
20,721
|
49,306
|
72,579
|
163,449
|
41,997
|
205,446
|
57,883
|
|
139,055
|
34,198
|
147,391
|
22.32%
|
22.65%
|
17.0%
|
79.56%
|
21,388
|
-1,658
|
-6,199
|
17.55%
|
19,730
|
13.36%
|
10.71%
|
0.00030737
|
0.00030737
|
2059人
|
2020年3月
|
116,637
|
21,668
|
22,442
|
16,888
|
53,155
|
63,482
|
146,861
|
34,672
|
181,533
|
43,583
|
|
120,798
|
26,495
|
132,886
|
18.58%
|
19.24%
|
14.48%
|
80.9%
|
12,737
|
-2,339
|
-5,660
|
10.92%
|
10,398
|
11.98%
|
9.64%
|
0.00025042
|
0.00025042
|
2026人
|
2019年3月
|
114,716
|
20,644
|
21,540
|
16,323
|
50,952
|
63,764
|
135,190
|
33,573
|
168,763
|
31,519
|
|
110,720
|
25,406
|
121,677
|
18.0%
|
18.78%
|
14.23%
|
80.11%
|
15,310
|
511
|
-3,708
|
13.35%
|
15,821
|
12.51%
|
9.98%
|
0.00024204
|
0.00024204
|
1951人
|
2018年3月
|
101,448
|
17,079
|
17,451
|
12,969
|
46,929
|
54,519
|
125,689
|
32,503
|
158,192
|
21,067
|
|
95,176
|
22,454
|
109,078
|
16.84%
|
17.2%
|
12.78%
|
79.45%
|
6,719
|
-11,342
|
-3,787
|
6.62%
|
-4,623
|
10.81%
|
8.39%
|
0.00019231
|
0.00019231
|
1928人
|
2017年3月
|
98,781
|
15,280
|
16,244
|
11,765
|
44,835
|
53,946
|
114,316
|
36,589
|
150,905
|
30,781
|
|
98,787
|
27,001
|
99,897
|
15.47%
|
16.44%
|
11.91%
|
75.75%
|
18,916
|
-5,750
|
-2,193
|
19.15%
|
13,166
|
10.84%
|
8.22%
|
0.00017442
|
0.00017442
|
1898人
|
2016年3月
|
84,209
|
8,549
|
8,952
|
6,346
|
44,016
|
40,193
|
102,762
|
32,608
|
135,370
|
20,435
|
|
85,401
|
20,569
|
89,658
|
10.15%
|
10.63%
|
7.54%
|
75.91%
|
8,915
|
-3,978
|
-1,907
|
10.59%
|
4,937
|
6.22%
|
4.79%
|
0.0000941
|
0.0000941
|
1843人
|
2015年3月
|
79,991
|
8,562
|
8,928
|
5,889
|
41,226
|
38,765
|
101,207
|
28,550
|
129,757
|
11,841
|
|
80,422
|
17,770
|
85,137
|
10.7%
|
11.16%
|
7.36%
|
78.0%
|
6,113
|
-3,718
|
-1,773
|
7.64%
|
2,395
|
6.06%
|
4.75%
|
0.00008726
|
0.00008726
|
1812人
|
2014年3月
|
76,517
|
8,038
|
8,598
|
5,750
|
39,033
|
37,484
|
93,186
|
25,002
|
118,188
|
11,097
|
|
74,683
|
15,257
|
81,105
|
10.5%
|
11.24%
|
7.51%
|
78.85%
|
6,015
|
-3,357
|
-1,606
|
7.86%
|
2,658
|
6.29%
|
4.96%
|
0.00008525
|
0.00008525
|
1790人
|
2013年3月
|
69,941
|
6,901
|
7,209
|
4,647
|
34,776
|
35,165
|
89,529
|
24,201
|
113,730
|
11,787
|
|
70,932
|
15,677
|
76,839
|
9.87%
|
10.31%
|
6.64%
|
78.72%
|
3,767
|
-2,026
|
-1,413
|
5.39%
|
1,741
|
5.34%
|
4.22%
|
0.00006887
|
0.00006887
|
1806人
|
2012年3月
|
67,304
|
|
6,193
|
3,715
|
|
|
84,566
|
21,738
|
106,304
|
19,665
|
|
|
|
|
0.0%
|
9.2%
|
5.52%
|
79.55%
|
3,658
|
-759
|
-1,341
|
5.44%
|
2,899
|
|
|
0.00005504
|
0.00005504
|
1823人
|
2011年3月
|
63,525
|
|
5,477
|
3,958
|
|
|
|
|
|
|
|
|
|
|
0.0%
|
8.62%
|
6.23%
|
|
|
|
|
|
|
|
|
0.00005862
|
0.00005862
|
1815人
|
2010年3月
|
62,932
|
|
6,786
|
4,096
|
|
|
|
|
|
|
|
|
|
|
0.0%
|
10.78%
|
6.51%
|
|
|
|
|
|
|
|
|
0.00006063
|
0.00006063
|
1749人
|